Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Fredun Pharmaceuticals Ltd

FREDUN

Fredun Pharmaceuticals Ltd

FREDUN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹371 cr, stock is ranked 2,000
High RiskStock is 3.91x as volatile as Nifty
792.850.76% (+6.00)
792.850.76% (+6.00)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹371 cr, stock is ranked 2,000
High RiskStock is 3.91x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹371 cr, stock is ranked 2,000
High RiskStock is 3.91x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
21.433.85—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.936.390.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Fredun Pharmaceuticals Ltd. is a pharmaceutical company engaged in the manufacturing and sale of pharmaceutical formulations. The Company’s products include I V fluids, disposable syringes, infusion sets, surgical gloves and cottons etc.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 29.08%, vs industry avg of 9.21%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.04% to 0.09%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 28.55%, vs industry avg of 15.17%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue43.1858.6159.7197.40113.29135.29226.09276.50349.07365.84
Raw Materialssubtract31.2534.2042.9865.9686.12100.60176.45245.57310.17324.07
Power & Fuel Costsubtract1.171.641.653.103.213.323.683.72
Employee Costsubtract3.834.925.198.048.958.6610.6611.53
Selling & Administrative Expensessubtract4.526.575.669.836.437.8012.7612.38
Operating & Other expensessubtract-2.296.04-1.64-0.14-0.275.337.04-27.34
Depreciation/Amortizationsubtract0.801.141.291.331.882.002.162.813.803.94
Interest & Other Itemssubtract2.061.871.943.134.484.374.7410.3213.6514.95
Taxes & Other Itemssubtract0.770.800.891.700.591.202.266.705.835.54
EPS4.465.976.0112.004.765.0415.0624.1233.3238.26
DPS0.600.600.600.650.660.700.700.700.000.70
Payout ratio0.130.100.100.050.140.140.050.030.000.02
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2019

Annual Report Unavailable

Investor Presentation

Jun 15PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Fredun Pharmaceuticals Ltd23.793.85—
Sun Pharmaceutical Industries Ltd45.086.430.75%
Cipla Ltd31.714.880.80%
Torrent Pharmaceuticals Ltd70.1816.950.82%

Price Comparison

Compare FREDUN with any stock or ETF
Compare FREDUN with any stock or ETF
FREDUN
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding49.17%0.00%1.60%0.00%49.24%

Dec 2023

Mar 2024

Apr 2024

Jun 2024

Shareholding History

AugSepDec '23MarAprJun0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 16, 2021

Final
Final | Div/Share: ₹0.70

Dividend/Share

₹0.70

Ex DateEx Date

Sep 16, 2021

Cash Dividend

Ex DateEx DateSep 16, 2019

Final
Final | Div/Share: ₹0.65

Dividend/Share

₹0.65

Ex DateEx Date

Sep 16, 2019

Cash Dividend

Ex DateEx DateSep 18, 2018

Final
Final | Div/Share: ₹0.60

Dividend/Share

₹0.60

Ex DateEx Date

Sep 18, 2018

Cash Dividend

Ex DateEx DateSep 20, 2017

Final
Final | Div/Share: ₹0.60

Dividend/Share

₹0.60

Ex DateEx Date

Sep 20, 2017

News & Opinions

Fredun Pharmaceuticals standalone net profit rises 72.08% in the June 2024 quarter

1 month agoBusiness Standard
Earnings
Fredun Pharmaceuticals standalone net profit rises 72.08% in the June 2024 quarter

Net profit of Fredun Pharmaceuticals rose 72.08% to Rs 4.13 crore in the quarter ended June 2024 as against Rs 2.40 crore during the previous quarter ended June 2023. Sales rose 26.64% to Rs 77.54 crore in the quarter ended June 2024 as against Rs 61.23 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales77.5461.23 27 OPM %13.5212.43 - PBDT6.575.00 31 PBT5.524.08 35 NP4.132.40 72 Powered by Capital Market - Live

1 month agoCapital Market - Live

Q1 results today: Adani Total Gas, Adani Wilmar among 95 companies to announce earnings on Monday

1 month agoEconomic Times

Fredun Pharmaceuticals standalone net profit rises 85.03% in the December 2022 quarter

1 year agoBusiness Standard

Multibagger stock hits 5% upper circuit as Board signs contracts worth ₹90 Cr

1 year agoLivemint

Fredun Pharmaceuticals standalone net profit rises 71.20% in the September 2022 quarter

1 year agoBusiness Standard

Fredun Pharmaceuticals standalone net profit rises 121.69% in the September 2021 quarter

2 years agoBusiness Standard

Fredun Pharmaceuticals receives prestigious award; Stock zooms 6%

3 years agoIndia Infoline

Fredun Pharmaceuticals standalone net profit rises 725.00% in the June 2021 quarter

3 years agoBusiness Standard

Fredun Pharmaceuticals reports standalone net profit of Rs 0.73 crore in the March 2021 quarter

3 years agoBusiness Standard